PENICILLIN V POTASSIUM- penicillin v potassium tablet, film coated Hikma Pharmaceuticals USA Inc.


Penicillin V Potassium Tablets

250 mg (400,000 Units) 500 mg (800,000 Units) Rx Only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets and other antibacterial drugs, penicillin V potassium tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Penicillin V is the phenoxymethyl analog of penicillin G. Penicillin V potassium is the potassium salt of penicillin V.



Penicillin V Potassium Tablets, USP for oral administration contain penicillin V potassium equivalent to 250 mg (400,000 units) or 500 mg (800,000 units) penicillin V. In addition, each tablet contains the following inactive ingredients: hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol, povidone, talc, titanium dioxide and microcrystalline cellulose.

CLINICAL PHARMACOLOGY

Penicillin V exerts a bactericidal action against penicillin-sensitive microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall mucopeptide. It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci. The drug exerts high *in vitro* activity against staphylococci (except penicillinase-producing strains), streptococci (groups A, C, G, H, L and M), and pneumococci. Other organisms sensitive *in vitro* to penicillin V are *Corynebacterium diphtheriae, Bacillus anthracis, Clostridia, Actinomyces bovis, Streptobacillus moniliformis, Listeria monocytogenes, Leptospira,* and *Neisseria gonorrhoeae. Treponema pallidum* is extremely sensitive.

The potassium salt of penicillin V has the distinct advantage over penicillin G in resistance to inactivation by gastric acid. It may be given with meals; however, blood levels are slightly higher when the drug is given on an empty stomach. Average blood levels are two to five times higher than the levels following the same dose of oral penicillin G and also show much less individual variation.

Once absorbed, penicillin V is about 80% bound to serum protein. Tissue levels are highest in the kidneys, with lesser amounts in the liver, skin, and intestines. Small amounts are found in all other body tissues and the cerebrospinal fluid. The drug is excreted as rapidly as it is absorbed in individuals with normal kidney function; however, recovery of the drug from the urine indicates that only about 25% of the dose given is absorbed. In neonates, young infants, and individuals with impaired kidney function, excretion is considerably delayed.

MICROBIOLOGY

Susceptibility Testing

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

INDICATIONS AND USAGE

Penicillin V Potassium Tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.

NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed.

The following infections will usually respond to adequate dosage of penicillin V.

Streptococcal Infections (without bacteremia)

Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas.

NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant.

Pneumococcal Infections

Mild to moderately severe infections of the respiratory tract.

Staphylococcal infections - penicillin G-sensitive

Mild infections of the skin and soft tissues.

NOTE: Reports indicate an increasing number of strains of staphylococci resistant to

penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections.

Fusospirochetosis (Vincent's gingivitis and pharyngitis)

Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

NOTE: Necessary dental care should be accomplished in infections involving the gum tissue.

Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions.

Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract¹. Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts).

Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that *alpha* hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen.

NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association¹.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets and other antibacterial drugs, Penicillin V Potassium Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

A previous hypersensitivity reaction to any penicillin is a contraindication.

WARNINGS

SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (anaphylactic) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH PENICILLIN V POTASSIUM TABLETS, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, PENICILLIN V POTASSIUM TABLETS SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. **SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.**

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including penicillin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS

Penicillin tablets should be used with caution in individuals with histories of significant allergies and/or asthma.

General

Prescribing penicillin V potassium tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

The oral route of administration should not be relied upon in patients with severe illness, or with nausea, vomiting, gastric dilatation, cardiospasm, or intestinal hypermotility.

Occasional patients will not absorb therapeutic amounts of orally administered penicillin.

In streptococcal infections, therapy must be sufficient to eliminate the organism (10-day minimum); otherwise the sequelae of streptococcal disease may occur. Cultures should be taken following completion of treatment to determine whether streptococci have been eradicated.

Prolonged use of antibiotics may promote the overgrowth of nonsusceptible organisms, including fungi. Should superinfection occur, appropriate measures should be taken.

Information for Patients

Patients should be counseled that antibacterial drugs including penicillin V potassium tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When penicillin V potassium tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by penicillin V potassium tablets or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

ADVERSE REACTIONS

Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin.

The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sicknesslike reactions, laryngeal edema, and anaphylaxis.

Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.

To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-233-2001, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

The dosage of penicillin V potassium tablets should be determined according to the sensitivity of the causative microorganisms and the severity of infection, and adjusted to the clinical response of the patient.

The usual dosage recommendations for adults and children 12 years and over are as follows:

Streptococcal Infections

Mild to moderately severe - of the upper respiratory tract and including scarlet fever and erysipelas: 125 to 250 mg (200,000 to 400,000 units) every 6 to 8 hours for 10 days.

Pneumococcal Infections

Mild to moderately severe - of the respiratory tract, including otitis media: 250 to 500 mg (400,000 to 800,000 units) every 6 hours until the patient has been afebrile for at least 2 days.

Staphylococcal Infections

Mild infections of skin and soft tissue (culture and sensitive tests should be performed): 250 to 500 mg (400,000 to 800,000 units) every 6 to 8 hours.

Fusospirochetosis (Vincent's infection) of the oropharynx.

Mild to moderately severe infections: 250 to 500 mg (400,000 to 800,000 units) every 6 to 8 hours.

For the prevention of recurrence following rheumatic fever and/or chorea: 125 to 250 mg (200,000 to 400,000 units) twice daily on a continuing basis.

For prophylaxis against bacterial endocarditis¹ in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures or surgical procedures of the upper respiratory tract: 2 gram of penicillin V (1 gram for children under 60 lbs.) 1 hour before the procedure, and then, 1 gram (500 mg for children under 60 lbs.) 6 hours later.

HOW SUPPLIED

Penicillin V Potassium Tablets, USP 250 mg (400,000 units) are white round film coated tablets bisected from one side and engraved with "W" on the upper side of the bisect and with "111" on the lower side.

Bottles of 100 Bottles of 1000

Penicillin V Potassium Tablets, USP 500 mg (800,000 units) are white modified capsule shaped film coated tablets bisected from both sides and engraved with "W" on one side of the bisect and "112" on the other side.

Bottles of 100 Bottles of 1000

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Keep container tightly closed. Dispense in a tight, light-resistant container, as defined in the USP using a child-resistant closure.

REFERENCES

1. American Heart Association.1984. Prevention of bacterial endocarditis. Circulation 70(6):1123A –1127A.

Distributed by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724 USA

Manufactured by: HIKMA Pharmaceuticals P.O. Box 182400

Amman 11118 - Jordan

Revised January 2023

Penicillin V Potassium Tablets, USP 250 mg (400,000 Units) 100 Tablets NDC 0143-9837-01



Penicillin V Potassium Tablets, USP 500 mg (800,000 Units) 100 Tablets NDC 0143-9836-01

NDC 0143 9836 01	Each tablet contains penicillin V potazsium equivalent to 500 mg (600,000 units) penicillin V.	
Penicillin V	USUAL BOBAGE 250 mg to 500 mg every 6 to 8 hours. 00 See accompanying prescribing information.	
Potassium Tablets, USP	See accompanying preserviting information. Multiple depensing package - This package is not for household use. Store at 20" to 25"C (68" to 77"F) [See UISP Controlled Room Temperature]. Dispense in a right light-veskitant container as defined in the UISP using a	
	Dispense in a tight, light-esistant container as defined in the USP using a child resistant closure.	
500 mg (800,000 Units)	KEEP THIS AND ALL NEDICATION OUT OF THE REACH OF	
100 TABLETS	Manufactured by Hikna Pharmassuficals	
R _c Only	PO Bos 152400, Amman 11118 Jordan 21.APVT5J1-F-082017	
WEST-WARD	Dist by West-Ward Pharmaceuticals Corp. Estonicem, NJ 07724	

PENICILLIN V POTASSIUM

penicillin v potassium tablet, film coated

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0143-9837	
Route of Administration ORAL				
	N/a : a tu a			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Stre	ength Strength	

In	Inactive Ingredients					
	Strength					
Ηλ	PROMELLOSES	(UNII: 3NXW29V3WO)	edient Name		j	
M	AGNESIUM STEA	RATE (UNII: 70097M6I30))			
PC	DLYETHYLENE G	LYCOL, UNSPECIFIED	(UNII: 3WJQ0SDW1A)			
PC	VIDONE (UNII: F	Z989GH94E)				
TA	LC (UNII: 7SEV7J	IR1U)				
Тľ	TANIUM DIOXIDI	(UNII: 15FIX9V2JP)				
CE	ELLULOSE, MICR	OCRYSTALLINE (UNII: C	DP1R32D61U)			
Product Characteristics						
Color white Score 2 pieces						
			Size		10mm	
	avor		Imprint Code		WW;111	
Co	Contains					
Packaging						
#	Item Code	Package I	Description	Marketing Start Date	Marketing End Date	
1	NDC:0143-9837- 01	100 in 1 BOTTLE; Type 0: Not a Combination Product		10/11/2013		
		3-9837- 1000 in 1 BOTTLE; Type 0: Not a Combination Product				

Marketing Information

Marketing	Application Number or Monograph	Marketing Start	Marketing End
Category	Citation	Date	Date
ANDA A	ANDA090549	10/11/2013	

PENICILLIN V POTASSIUM

penicillin v potassium tablet, film coated

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0143-9836
Route of Administration	ORAL		

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
PENICILLIN V POTASSIUM (UNII: 146T0TU1JB) (PENICILLIN V - UNII:Z61I075U2W)	PENICILLIN V	500 mg		

Inactive Ingredients					
	Ingredient I	Name	Strength		
HYPROMELLOSES (UNII: 3N)	(W29V3WO)				
MAGNESIUM STEARATE (UN	II: 70097M6I30)				
POLYETHYLENE GLYCOL, U	NSPECIFIED (UNII: 3W)	QOSDW1A)			
POVIDONE (UNII: FZ989GH94	POVIDONE (UNII: FZ989GH94E)				
TALC (UNII: 7SEV7J4R1U)					
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)					
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)					
Product Characteristics					
Color	white	Score	2 pieces		
Shape	CAPSULE	Size	7mm		
Flavor		Imprint Code	W;112		

Packaging

Contains

#	ltem Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0143-9836- 10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	10/11/2013	
2	2 NDC:0143-9836- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product		10/11/2013	
Marketing Information				

Marketing	Application Number or Monograph	Marketing Start	Marketing End
Category	Citation	Date	Date
ANDA	ANDA090549	10/11/2013	

Labeler - Hikma Pharmaceuticals USA Inc. (001230762)

Establishment			
Name	Address	ID/FEI	Business Operations
West-Ward Columbus Inc.		058839929	label(0143-9837, 0143-9836)

Revised: 1/2023

Hikma Pharmaceuticals USA Inc.